Giorgio V. Scagliotti

Turin, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 290 publications

Targeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance.

Targeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: December 13, 2025

Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT).

Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 14, 2025

Unraveling lung cancer dynamics: a new metabolic signature improving the prediction of recurrence in resected lung adenocarcinoma.

Unraveling lung cancer dynamics: a new metabolic signature improving the prediction of recurrence in resected lung adenocarcinoma.

Journal: Journal of translational medicine

Published: September 10, 2025

Shifting Shapes: The Endothelial-to-Mesenchymal Transition as a Driver for Cancer Progression.

Shifting Shapes: The Endothelial-to-Mesenchymal Transition as a Driver for Cancer Progression.

Journal: International journal of molecular sciences

Published: June 03, 2025

Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy.

Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy.

Journal: European urology oncology

Published: April 08, 2025

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Journal: Nature

Published: February 27, 2025

Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma.

Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma.

Journal: Journal of experimental & clinical cancer research : CR

Published: October 01, 2024

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 03, 2024

Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives.

Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives.

Journal: Clinical genitourinary cancer

Published: April 25, 2024

Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data.

Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data.

Journal: JTO clinical and research reports

Published: April 16, 2024

TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer.

TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 14, 2024

Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets.

Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets.

Journal: Expert opinion on therapeutic targets

Published: January 18, 2024

Showing 1-12 of 290

Last Updated: 09/26/2026